138
Views
1
CrossRef citations to date
0
Altmetric
Original Research

The Immunohistochemical Expression MTA 1 Protein and its Prognostic Value in Pancreatic Cancer

, MD, PhD, , MD, PhD, , MD, PhD, , MD, PhD, , MD, PhD, , MD, PhD, , MD, , MD, PhD & , MD, PhD show all
Pages 142-150 | Received 27 Nov 2016, Accepted 06 Jan 2017, Published online: 10 Feb 2017

REFERENCES

  • Siegel R, Miller KD, Zouz JA. Cancer statistics 2015. CA Cancer J Clin. 2015;65:5–29.
  • Jemal A, Brady F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.
  • Yeo TP. Demographics, epidemiology, and inheritance of pancreatic ductal adenocarcinoma. Semin Oncol. 2015;42:8–18.
  • Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg. 2000;4:567–579.
  • Winter JM, Cameron JL, Campbell KA, et al. 1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience. J Gastrointest Surg. 2006;10:1199–1211.
  • Kaur S, Braine MJ, Jain M, et al. Early diagnosis of pancreatic cancer: challenges and new developments. Biomark Med. 2012;6:507–612.
  • Campbell PJ, Yachida S, Mudie LJ, et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 2010;467:1109–1013.
  • Hingorani SR, Petricoin EF, Maitra A, et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell. 2003;4:437–450.
  • Tang J, Zhu Y, Xie K, et al. The role of the AMOP domain in MUC4/Y-promoted tumour angiogenesis and metastasis in pancreatic cancer. J Exp Clin Cancer Res. 2016;35:91.
  • Wilts IT, Hutten BA, Meijers JC, et al. PO-28 - protein C levels are associated with mortality in patients with advanced cancer. Thromb Res. 2016;140(Suppl 1):S186–S187.
  • Sheng W, Dong M, Chen C, et al. Musashi2 promotes the development and progression of pancreatic cancer by down-regulating Numb protein. Oncotarget 2016.doi: 10.18632/oncotarget.8736. [Epub ahead of print].
  • Shinkai K, Nakano K, Cui L, et al. Nuclear expression of Y-box binding protein-1 is associated with poor prognosis in patients with pancreatic cancer and its knockdown inhibits tumor growth and metastasis in mice tumor models. Int J Cancer. 2016;139:433–445.
  • Xu Y, Li Z, Jiang P, et al. The co-expression of MMP-9 and Tenascin-C is significantly associated with the progression and prognosis of pancreatic cancer. Diagn Pathol. 2015;10:211.
  • Kumar R, Wang RA, Bagheri-Yarmand R. Emerging roles of MTA family members in human cancers. Semin Oncol. 2003;30(Suppl 16):30–37.
  • Miyake K, Yoshizumi T, Imura S, et al. Expression of hypoxia-inducible factor-1alpha, histone deacetylase 1, and metastasis-associated protein 1 in pancreatic carcinoma: correlation with poor prognosis with possible regulation. Pancreas 2008;36:e1–9.
  • Iwahashi S, Shimada M, Utsunomiya T, et al. Histone deacetylase inhibitor augments anti-tumor effect of gemcitabine and pegylated interferon-α on pancreatic cancer cells. Int J Clin Oncol. 2011;16:671–678.
  • Pan Y, Wang L, Kang SG, et al. Gd-metallofullerenol nanomaterial suppresses pancreatic cancer metastasis by inhibiting the interaction of histone deacetylase 1 and metastasis-associated protein 1. ACS Nano. 2015;9:6826–6836.
  • Manavathi B, Singh K, Kumar R. MTA family of coregulators in nuclear receptor biology and pathology. Nucl Recept Signal. 200730;5:e010.
  • Millard CJ, Fairall L, Schwabe JW. Towards an understanding of the structure and function of MTA1.Cancer Metastasis Rev. 2014;33:857–867.
  • Toh Y, Pencil SD, Nicolson GL. A novel candidate metastasis associated gene, MTA 1, differentially expressed in highly metastatic mammary adenocarcinoma cell lines. cDNAclining, expression and protein analyses. J Biol Chem. 1994;269:22958–22963.
  • Nicolson GL, Nawa A, Toh Y, et al. Tumor metastasis- associated human MTA 1 gene and its MTA 1 protein product: role in epithelial cancer cell invasion, proliferation and nuclear regulation. Clin Exp Metast. 2003;20:19–24.
  • Simpson A, Uitto J, Rodeck U, et al. Differential expression and sub cellular distribution of the mouse metastasis- associated proteins MTA 1 and MTA 3. Gene 2001;273:29–39.
  • Solari F, Bateman A, Ahringer J. The Caenorhabditiselegans genes egl- 27 and egr- 1 are similar to MTA 1, a member of a chromatin regulatory complex, and are redundantly required for embryonic patterning. Development 1999;126:2483–2494.
  • Hofer, MA, Genze F, Gierschik P, et al. Expression of MTA 1 promotes motility and invasiveness of PANC 1 pancreatic carcinoma cells. Br J Cancer. 2004;90:455–462.
  • Iguchi H, Imura G, Toh Y, et al. Expression of MTA 1, a metastasis associated gene with histone deacetylase activity in pancreatic cancer. Int J Oncol. 2000;16:1211–1214. [PMID: 10811997]
  • Pavlidis TE, Pavlidis ET, Sakantamis AK. Current opinion on lymphadenectomy in pancreatic cancer surgery. Hepatobiliary Pancreat Dis Int. 2011;10:21–25.
  • Toh Y, Oki E, Oda S, et al. Over expression of the MTA 1 gene in gastrointestinal carcinomas: correlation with invasion and metastasis. Int J Cancer. 1997;74:459–463.
  • Xue Y, Wong J, Tony-Moreno G, et al. NURD, a novel complex with both ATP- dependent chromatin remodeling and histone deacetylase activities. Mol Cell. 1998;2:851–861.
  • Morikawa K, Walker SM, Jessup M, et al. In vivo selection of highly metastatic cells from surgical specimens of different primary human colon carcinomas implanted into nude mice. Cancer Res. 1998;48:1943–1948.
  • Kawarada Y, Isaji S. Stage classifications of pancreatic cancer: comparison of the Japanese and UICC classifications and proposal for a new staging system. Pancreas 1998;16:255–264.
  • Mahoney MG, Simpson A, Jost M, et al. Metastasis associated protein (MTA 1) enhances migration, invasion and anchorage- independent survival of immortalized human keratinocytes. Oncogene 2002;21:2161–2170.
  • Toh Y, Nicolson GL. The role of the MTA family and their encoded proteins in human cancers: molecular functions and clinical implications. Clin Exp Metastasis. 2009;26:215–227.
  • Nicoloso MS, Spizzo R, Shimizu M, et al. MicroRNAs–the micro steering wheel of tumour metastases. Nat Rev Cancer. 2009;9:293–302.
  • Choi DH, Park SJ, Kim HK. miR-215 overexpression distinguishes ampullary carcinomas from pancreatic carcinomas. Hepatobiliary Pancreat Dis Int. 2015;14:325–329.
  • Li Y, Vandenboom TG II, WangZ, et al. miR-146a suppresses invasion of pancreatic cancer cells. Cancer Res. 2010;70:1486–1495.
  • Xu XD, Hu J, Wang M, et al,. Circulating myeloid-derived suppressor cells in patients with pancreatic cancer. Hepatobiliary Pancreat Dis Int. 2016;15:99–105. [PMID: 26818550]
  • Zhu Z, Liu T, Han F, et al. Mutations in the p16 gene in DMBA-induced pancreatic intraepithelial neoplasia and pancreatic cancer in rats. Hepatobiliary Pancreat Dis Int. 2015;14:208–214.
  • Zhou L, Li J, Zhao YP, et al. Prognostic significance of epidermal growth factor-like domain 7 in pancreatic cancer. Hepatobiliary Pancreat Dis Int . 2014;13:523–528.
  • Zhang Q, Zeng L, Chen Y, et al. Pancreatic cancer epidemiology. Detection and management. Gastroenterol Res Pract. 2016;2016:89623.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.